Carlyle Group has agreed to pay $435m for the biologics research technology provider, which has raised $86m from investors including Novo.
Pharmaceutical firm Novo is set to exit US-based life science research tool developer Unchained Labs in a $435m acquisition by private equity firm Carlyle Group agreed yesterday.
Unchained Labs provides a range of life science tools used by biologics and gene therapy researchers to analyse and identify large, complex molecules. It has eight product lines and expects to generate over $75m of revenue in 2021.
Tim Harkness, Unchained Labs’ founder and CEO, said: “The Unchained team has solved a ton…
